SCHEMBL6715194

SCHEMBL6715194

Cc1noc(C)c1S(=O)(=O)Nc1ccc(C2=NCCc3ccccc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.52
LMNA P02545 1/20 0.52
ALDH1A1 P00352 4/20 0.50
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 1/20 0.46
MAPT P10636 3/20 0.44
POLB P06746 2/20 0.44
TP53 P04637 1/20 0.44
ACLY P53396 1/20 0.44
BRD4 O60885 1/20 0.43
BRD2 P25440 1/20 0.43
BRD3 Q15059 1/20 0.43
NR3C1 P04150 2/20 0.43
NR3C2 P08235 1/20 0.43
GAA P10253 1/20 0.43
PGR P06401 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6718862 0.89 ALDH1A1 (0.52) HPGDLMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL7213745 0.87 BRD4 (0.49) HPGDLMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL6720414 0.86 ALDH1A1 (0.47) HPGDLMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL6718037 0.84 MEN1 (0.44) HPGDLMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL6718857 0.80 ALDH1A1 (0.48) HPGDLMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL6714960 0.79 PKM (0.49) ALDH1A1MAPTGAA
SCHEMBL6720559 0.78 ALDH1A1 (0.48) HPGDLMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL6720489 0.78 ALDH1A1 (0.48) HPGDLMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL6720382 0.78 ALDH1A1 (0.48) HPGDLMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL6716845 0.76 GSPT1 (0.46) LMNAMAPTPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed
EP-1337515-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-08-27 EP disclosed
WO-2002040450-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A HPGD 208/4885LMNA 1790/4885ALDH1A1 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.